6-Ethoxy-2-(tri-n-butylstannyl)-pyridine | 227305-52-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-Ethoxy-2-(tri-n-butylstannyl)-pyridine
• 英文别名: 2-ethoxy-6-(tributylstannyl)pyridine；Tri-n-butyl(6-ethoxy-2-pyridyl)tin；tributyl-(6-ethoxypyridin-2-yl)stannane
• CAS: 227305-52-4
• 化学式: C₁₉H₃₅NOSn
• 分子量: 412.203
• InChiKey: IDMFTWUNPWQGQT-UHFFFAOYSA-N

物化性质

• 沸点：
  416.8±55.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.54
• 重原子数：
  22
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(3-((5-bromothiophen-2-yl)methyl)-4-chlorophenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 、 6-Ethoxy-2-(tri-n-butylstannyl)-pyridine 以to give 1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-4-chloro-3-(5-(6-ethoxy-2-pyridyl)-2-thienylmethyl) benzene as colorless crystals的产率得到1-(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl)-4-chloro-3-(5-(6-ethoxy-2-pyridyl)-2-thienylmethyl) benzene
  参考文献：
  名称：

  Glucopyranoside compound

  摘要：

  该化合物的化学式为：其中环A和环B为：（1）环A为可选取代的不饱和单环杂环，环B为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，（2）环A为可选取代的苯环，环B为可选取代的不饱和单环杂环或可选取代的不饱和融合杂双环，或（3）环A为可选取代的不饱和融合杂双环，环B独立地为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；X为碳原子或氮原子；Y为—(CH2)n—（n为1或2）；或其药学上可接受的盐或前药。

  公开号：

  US08222219B2
• 作为产物：
  描述：

  2-溴-6-乙氧基吡啶 、 三丁基氯化锡 在 正丁基锂 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 以34%的产率得到6-Ethoxy-2-(tri-n-butylstannyl)-pyridine
  参考文献：
  名称：

  US6387931

  摘要：

  公开号：

文献信息

• Novel compounds
  申请人：Nomura Sumihiro

  公开号：US20050233988A1

  公开（公告）日：2005-10-20

  A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH 2 ) n — (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  一种化合物，其化学式为：其中环A和环B分别为：（1）环A为可选取代的不饱和单环杂环，环B为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；（2）环A为可选取代的苯环，环B为可选取代的不饱和单环杂环或可选取代的不饱和融合杂双环；或（3）环A为可选取代的不饱和融合杂双环，环B独立地为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；X为碳原子或氮原子；Y为—（CH2）n—（n为1或2）；其药学上可接受的盐或其前药。
• Hydroxamic acid derivatives as matrix metalloprotease (MMP) inhibitors
  申请人：Warner-Lambert Company

  公开号：US06495568B1

  公开（公告）日：2002-12-17

  Compounds of formula (I): or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein the broken line represents an optional bond; A is C or CH; B is CH2, O or absent; R1 and R2 are each independently selected from hydrogen, C1 to C6 alkyl optionally substituted with C1 to C4 alkoxy or phenyl, and C1 to C6 alkenyl; or, together with the carbon atom to which they are attached, form a C3 to C6 cycloalkyl group which optionally incorporates a heteroatom linkage selected from O, SO, SO2 and NR6 or which is optionally benzo-fused; R3 is hydrogen, halo, R7 or OR7; R4 is hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, trifluoromethyl or halo; R6 is hydrogen or C1 to C4 alkyl; R7 is an optionally substituted monocyclic or bicyclic ring system; m is 1 or 2; and n is 0, 1 or 2; with the proviso that B is not O when A is C; are MMP inhibitors useful in the treatment of, inter alia, tissue ulceration, wound repair and skin diseases.

  化合物的式子(I)：或其药学上或兽医学上可接受的盐，或这两个实体的药学上或兽医学上可接受的溶剂化物，其中断线代表可选键；A为C或CH；B为CH2、O或不存在；R1和R2各自独立地选自氢、C1至C6烷基，可选地被C1至C4烷氧基或苯基取代，以及C1至C6烯基；或与它们所连接的碳原子一起形成C3至C6环烷基，该环烷基可选地包括从O、SO、SO2和NR6中选择的杂原子键合或可选地与苯融合；R3为氢、卤素、R7或OR7；R4为氢、C1至C4烷基、C1至C4烷氧基、三氟甲基或卤素；R6为氢或C1至C4烷基；R7为可选取代的单环或双环环系统；m为1或2；n为0、1或2；但当A为C时，B不为O；这些MMP抑制剂在治疗组织溃疡、伤口修复和皮肤疾病等方面非常有用。
• Glucopyranoside compound
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US08222219B2

  公开（公告）日：2012-07-17

  A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  该化合物的化学式为：其中环A和环B为：（1）环A为可选取代的不饱和单环杂环，环B为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，（2）环A为可选取代的苯环，环B为可选取代的不饱和单环杂环或可选取代的不饱和融合杂双环，或（3）环A为可选取代的不饱和融合杂双环，环B独立地为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；X为碳原子或氮原子；Y为—(CH2)n—（n为1或2）；或其药学上可接受的盐或前药。
• Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors
  作者：Bin Wu、Hui-Ling Wang、Victor J. Cee、Brian A. Lanman、Thomas Nixey、Liping Pettus、Anthony B. Reed、Ryan P. Wurz、Nadia Guerrero、Christine Sastri、Jeff Winston、J. Russell Lipford、Matthew R. Lee、Christopher Mohr、Kristin L. Andrews、Andrew S. Tasker

  DOI：10.1016/j.bmcl.2014.12.091

  日期：2015.2

  PIM kinases are a family of Ser/Thr kinases that are implicated in tumorigenesis. The discovery of a new class of PIM inhibitors, 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines, is discussed with optimized compounds showing excellent potency against all three PIM isoforms. (C) 2015 Elsevier Ltd. All rights reserved.
• US6387931
  申请人：——

  公开号：——

  公开（公告）日：——